334 related articles for article (PubMed ID: 31570822)
1. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
Staaf J; Glodzik D; Bosch A; Vallon-Christersson J; Reuterswärd C; Häkkinen J; Degasperi A; Amarante TD; Saal LH; Hegardt C; Stobart H; Ehinger A; Larsson C; Rydén L; Loman N; Malmberg M; Kvist A; Ehrencrona H; Davies HR; Borg Å; Nik-Zainal S
Nat Med; 2019 Oct; 25(10):1526-1533. PubMed ID: 31570822
[TBL] [Abstract][Full Text] [Related]
2. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
4. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
Zhao EY; Shen Y; Pleasance E; Kasaian K; Leelakumari S; Jones M; Bose P; Ch'ng C; Reisle C; Eirew P; Corbett R; Mungall KL; Thiessen N; Ma Y; Schein JE; Mungall AJ; Zhao Y; Moore RA; Den Brok W; Wilson S; Villa D; Shenkier T; Lohrisch C; Chia S; Yip S; Gelmon K; Lim H; Renouf D; Sun S; Schrader KA; Young S; Bosdet I; Karsan A; Laskin J; Marra MA; Jones SJM
Clin Cancer Res; 2017 Dec; 23(24):7521-7530. PubMed ID: 29246904
[No Abstract] [Full Text] [Related]
5. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Chopra N; Tovey H; Pearson A; Cutts R; Toms C; Proszek P; Hubank M; Dowsett M; Dodson A; Daley F; Kriplani D; Gevensleben H; Davies HR; Degasperi A; Roylance R; Chan S; Tutt A; Skene A; Evans A; Bliss JM; Nik-Zainal S; Turner NC
Nat Commun; 2020 May; 11(1):2662. PubMed ID: 32471999
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
10. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
[TBL] [Abstract][Full Text] [Related]
11. The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.
Štancl P; Hamel N; Sigel KM; Foulkes WD; Karlić R; Polak P
Front Genet; 2022; 13():852159. PubMed ID: 35783256
[No Abstract] [Full Text] [Related]
12. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Glodzik D; Bosch A; Hartman J; Aine M; Vallon-Christersson J; Reuterswärd C; Karlsson A; Mitra S; Niméus E; Holm K; Häkkinen J; Hegardt C; Saal LH; Larsson C; Malmberg M; Rydén L; Ehinger A; Loman N; Kvist A; Ehrencrona H; Nik-Zainal S; Borg Å; Staaf J
Nat Commun; 2020 Jul; 11(1):3747. PubMed ID: 32719340
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
16. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
17. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
18. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
20. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
